X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs BIOCON LTD - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE BIOCON LTD CADILA HEALTHCARE/
BIOCON LTD
 
P/E (TTM) x 20.1 92.6 21.7% View Chart
P/BV x 4.8 7.8 60.8% View Chart
Dividend Yield % 0.9 0.1 582.1%  

Financials

 CADILA HEALTHCARE   BIOCON LTD
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
BIOCON LTD
Mar-18
CADILA HEALTHCARE/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs5581,188 47.0%   
Low Rs362305 118.5%   
Sales per share (Unadj.) Rs116.368.7 169.2%  
Earnings per share (Unadj.) Rs17.97.6 236.6%  
Cash flow per share (Unadj.) Rs23.114.0 165.6%  
Dividends per share (Unadj.) Rs3.501.00 350.0%  
Dividend yield (eoy) %0.80.1 568.3%  
Book value per share (Unadj.) Rs85.486.3 98.9%  
Shares outstanding (eoy) m1,023.74600.00 170.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.010.9 36.4%   
Avg P/E ratio x25.798.9 26.0%  
P/CF ratio (eoy) x19.953.4 37.2%  
Price / Book Value ratio x5.48.6 62.3%  
Dividend payout %19.613.2 147.9%   
Avg Mkt Cap Rs m470,664447,900 105.1%   
No. of employees `00011.86.1 192.2%   
Total wages/salary Rs m18,5459,311 199.2%   
Avg. sales/employee Rs Th10,072.76,705.8 150.2%   
Avg. wages/employee Rs Th1,569.11,514.2 103.6%   
Avg. net profit/employee Rs Th1,547.7736.9 210.0%   
INCOME DATA
Net Sales Rs m119,04941,234 288.7%  
Other income Rs m1,1322,062 54.9%   
Total revenues Rs m120,18143,296 277.6%   
Gross profit Rs m28,4758,291 343.4%  
Depreciation Rs m5,3883,851 139.9%   
Interest Rs m911615 148.1%   
Profit before tax Rs m23,3085,887 395.9%   
Minority Interest Rs m628213 294.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6441,569 359.7%   
Profit after tax Rs m18,2924,531 403.7%  
Gross profit margin %23.920.1 119.0%  
Effective tax rate %24.226.7 90.9%   
Net profit margin %15.411.0 139.8%  
BALANCE SHEET DATA
Current assets Rs m82,00541,486 197.7%   
Current liabilities Rs m60,72021,413 283.6%   
Net working cap to sales %17.948.7 36.7%  
Current ratio x1.41.9 69.7%  
Inventory Days Days7364 114.3%  
Debtors Days Days9894 104.4%  
Net fixed assets Rs m83,70350,661 165.2%   
Share capital Rs m1,0243,000 34.1%   
"Free" reserves Rs m86,42148,808 177.1%   
Net worth Rs m87,44551,808 168.8%   
Long term debt Rs m25,55117,898 142.8%   
Total assets Rs m180,65399,897 180.8%  
Interest coverage x26.610.6 251.5%   
Debt to equity ratio x0.30.3 84.6%  
Sales to assets ratio x0.70.4 159.7%   
Return on assets %10.65.2 206.4%  
Return on equity %20.98.7 239.2%  
Return on capital %22.09.6 228.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68312,058 354.0%   
Fx outflow Rs m11,2427,348 153.0%   
Net fx Rs m31,4414,710 667.5%   
CASH FLOW
From Operations Rs m9,1936,621 138.8%  
From Investments Rs m-9,737-6,840 142.4%  
From Financial Activity Rs m515-2,397 -21.5%  
Net Cashflow Rs m-29-2,612 1.1%  

Share Holding

Indian Promoters % 74.8 40.4 185.1%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 8.3 8.4 98.8%  
FIIs % 5.9 10.7 55.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 19.9 55.3%  
Shareholders   44,069 109,995 40.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA LTD  SANOFI INDIA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 18, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS